📰 Affimed News
Page 5 - Affimed News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Affimed. Real-time updates on events, politics, business and more.
May 4, 2023
Shares of Affimed (NASDAQ:AFMD – Get Rating) have been assigned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the […]
May 3, 2023
Affimed (NASDAQ:AFMD – Get Rating) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 5,830,000 shares, a growth of 9.2% from the March 31st total of 5,340,000 shares. Based on an average trading volume of 1,010,000 shares, the days-to-cover ratio […]
May 2, 2023
Shares of Affimed (NASDAQ:AFMD – Get Rating) have earned a consensus rating of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The […]
April 17, 2023
Affimed (NASDAQ:AFMD – Get Rating) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 5,340,000 shares, a growth of 36.2% from the March 15th total of 3,920,000 shares. Based on an average trading volume of 1,170,000 shares, the short-interest ratio is currently 4.6 […]
April 9, 2023
Affimed (NASDAQ:AFMD – Get Rating) has been given an average rating of “Moderate Buy” by the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The […]
April 9, 2023
Affimed (NASDAQ:AFMD – Get Rating) has been given an average rating of “Moderate Buy” by the eight analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The […]
March 30, 2023
Several brokerages have updated their recommendations and price targets on shares of Affimed (NASDAQ: AFMD) in the last few weeks: 3/27/2023 – Affimed had its “overweight” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $7.00 price target on the stock. 3/24/2023 – Affimed was downgraded by analysts at StockNews.com from […]
March 28, 2023
StockNews.com downgraded shares of Affimed (NASDAQ:AFMD – Get Rating) from a hold rating to a sell rating in a research report released on Friday morning. A number of other analysts have also issued reports on the company. Truist Financial reduced their target price on Affimed from $12.00 to $8.00 in a report on Monday, December […]
March 28, 2023
Wells Fargo & Company reissued their overweight rating on shares of Affimed (NASDAQ:AFMD – Get Rating) in a research note published on Monday morning, Benzinga reports. Wells Fargo & Company currently has a $7.00 price objective on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on the stock. […]
March 27, 2023
StockNews.com lowered shares of Affimed (NASDAQ:AFMD – Get Rating) from a hold rating to a sell rating in a research note released on Friday morning. Several other research firms have also recently weighed in on AFMD. Stifel Nicolaus lowered their price target on Affimed from $2.00 to $1.00 and set a hold rating on the […]